Skip to content

Identification of an Fgd5-positive subset of iNKT1 cells with enhanced cytotoxicity.

Aug 2026 · Journal of Immunology · Vol 215 8 · 0 citations · 46 references
Medicine

Abstract

Invariant natural killer T (iNKT) cells are unconventional ɑβ T cells that respond to lipid-based antigens. They play a vital role in response to infections and are involved in diseases such as allergic asthma and cancer. Despite clear immunological roles across multiple diseases, remarkably few tools exist to study iNKTs in vivo. In this study, we report that the Fgd5ZsGreen/+ reporter mouse widely used to study hematopoietic stem cells (HSCs) can dually serve to identify rare immune cell populations, including a subset of iNKTs. Specifically, we show that a "non-HSC" population of CD45+Fgd5ZsGreen+ cells reside in multiple organs including the lungs, liver, spleen, and thymus. The majority of these Fgd5ZsGreen+ cells do not express canonical HSC markers but instead express CD5. RNA sequencing of CD5+EPCR-Fgd5ZsGreen+ bone marrow cells showed greatest similarity to iNKT cells, and these findings were corroborated by additional cell surface marker analysis of TCRβint CD1d-PBS57+ iNKT cells in reporter mouse tissues. We found that roughly 20% of total thymic iNKT cells were Fgd5-ZsGreen+ and that these cells predominantly coexpressed NK1.1 and CD122, consistent with an iNKT1 cell phenotype. Transcriptomic and proteomic profiling of sorted Fgd5-ZsGreen- and Fgd5-ZsGreen+ iNKT cells revealed a number of key genes involved in cytotoxic responses as distinct between the two iNKT cell populations. These different cytotoxic profiles were further supported by cytokine expression following stimulation, indicating the potential existence of disparate iNKT1 subsets. Together, these data implicate Fgd5 expression as a powerful new tool for phenotyping and tracking cytotoxic iNKT1 cell subsets in vivo.

View source

Similar papers

Open access Oct 2026

T-B interactions yield CD3+ B cells and CD20+ T cells with pathogenic features in multiple sclerosis.

Classically, B and T cells are differentiated by their mutually exclusive expression of surface markers such as CD3 and CD20, but it is now established that a few percent of T cells in human blood display also CD20. We analyzed CD3+CD20+ cells in detail by combining single-cell proteogenomics, FACS, and ImageStream. Th...

Selia Baier, Zhong-Yi Wang, N. Loll et al. · 0 citations
Review Open access Sep 2026

CD4+ cytotoxic T cells: context-dependent effectors in health and disease

This review highlights recent advances in understanding the development, regulation, and effector functions of CD4 + CTLs, while also addressing the limitations and challenges in targeting them therapeutically.

Hao-Yang Yu, Jia-Xin Liang, Qi-Xuan Gu et al. · 0 citations
Open access Oct 2026

TCR clonotyping of paired blood and tonsillar T-follicular cells reveals the mixed origin of CD38high Tfrs

Circulating T follicular regulatory (cTfr) cells are measured as blood biomarkers after vaccination, in autoimmune disease (e.g., lupus, rheumatoid arthritis) and cancer immunotherapy, yet whether they originate from natural Tregs (yielding nTfr) or germinal center T follicular helper (GC Tfh) cells (yielding iTfr) rem...

S. Sokolova, Vladimir A. Grigoriants, I. Shagina et al. · 0 citations
Open access Sep 2026

Single-cell transcriptomics reveal tissue-specific neutrophil heterogeneity and functional reprogramming in autoimmunity.

Neutrophils are increasingly recognized as key regulators of autoimmune responses; however, the mechanisms by which their heterogeneity is influenced across various tissues in autoimmunity remain insufficiently understood. Here, using experimental autoimmune encephalomyelitis (EAE), we show that splenic and bone marrow...

Qian-Ling Jiang, Gao-Chen Zhu, Wen Si et al. · 0 citations
Open access Oct 2026

Targeting CD28 on T lineage malignancies with chimeric antigen receptor T cells

Currently, no immunotherapy is approved for T cell acute lymphoblastic leukemia (T‑ALL). High initial response rates to CD7‑directed chimeric antigen receptor (CAR) T cells are limited by profound T cell aplasia and CD7‑negative immune escape, underscoring the need for alternative targets. Here, we show that CD28 is ov...

Semjon Willier, Julian Färber, Theodora Ispyrlidou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.